CHINA
13:14, January 20, 2023
(File photo: CGTN)
Chinese drugmaker Sinopharm said that its mRNA COVID-19 vaccine against the Omicron variant has received government approval on Thursday to begin clinical trials.
The company has built a 2 billion dose annual capacity production line in Shanghai and will continue to study the vaccine's efficacy.
We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies
